TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE
Total received in grants · trailing 12 months
$2.7M
$0for every U.S. household÷ 131M U.S. households
In perspective
0.0%of all $162.9B in tracked grants
2separate grants, trailing 12 months
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE has received $2.7M across 2 federal grants of $1M or more on record.
Data as of July 24, 2026. Source: USAspending.gov, prime contract awards $1M+. Federal spending data lags and has known gaps. This is not a real-time or complete record.
Grants by agency
Where this recipient’s grant dollars come from.
All grant awards
Swipe to see description and amount →
| Agency | Description | Amount |
|---|---|---|
| Department of Health and Human Services | ENGAGING THE SUBGENUAL CINGULATE WITH BRAIN STIMULATION FOR DEPRESSION - ABSTRACT THE SUBGENUAL ANTERIOR CINGULATE CORTEX (SGACC) HAS DOMINATED THE LITERATURE UTILIZING REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (RTMS) TO TREAT DEPRESSION FOR GOOD REASON: TREATMENT FOCUSING ON THE FRONTAL-SGACC BRAIN CIRCUIT IS EFFECTIVE AND CHANGES IN RESTING FMRI CONNECTIVITY WITH THE SGACC ACCOMPANY SYMPTOM IMPROVEMENTS. HOWEVER, IT HAS NOT YET BEEN PROVEN THAT TMS ACTUALLY ENGAGES THE SGACC WHICH WOULD SUPPORT CONTINUED FOCUS ON THIS CIRCUIT AT THE EXCLUSION OF OTHER POTENTIAL TARGETS FROM THE FMRI LITERATURE. WITH THE APPLICATION OF INTERLEAVED TMS/FMRI, IT IS POSSIBLE TO CAPTURE BRAIN RESPONSES CAUSED BY TMS TO ANY BRAIN SURFACE SITE. USING RESTING FMRI CONNECTIVITY TO GUIDE TMS TARGETING, WE SEEK TO ESTABLISH NEUROMODULATION OF THE SGACC PATHWAY (R61, AIM 1) AND THE BEST CONNECTIVITY PIPELINE FOR ROBUSTLY ENGAGING THE SGACC (R61, AIM 2). UPON ESTABLISHING THESE SUCCESSFUL BENCHMARKS, THE R33 PHASE WILL DEMONSTRATE THAT THE SGACC EVOKED RESPONSE AT BASELINE PREDICTS DEPRESSION IMPROVEMENT WHEN TREATMENT DELIVERED TO THIS SAME CIRCUIT (R33, AIM1). TO CEMENT THE RELATIONSHIP BETWEEN MODULATION OF THE FRONTAL-SGACC CIRCUIT WITH TREATMENT AND DEPRESSION IMPROVEMENT, WE HYPOTHESIZE AN ASSOCIATION BETWEEN BRAIN CHANGES AND CLINICAL CHANGES (R33, AIM 2). WE HYPOTHESIZE THAT THE R33 CLINICAL ASSOCIATIONS WITH EVOKED BRAIN RESPONSES WILL BE ESTABLISHED FOR ACTIVE BUT NOT FOR SHAM RTMS. TOGETHER, THIS RESEARCH WILL ELUCIDATE BASIC MECHANISMS OF RTMS TREATMENT THAT WILL ACCELERATE BRAIN CIRCUIT TARGETED NEUROTHERAPEUTICS. | $1,396,404 |
| Department of Health and Human Services | TERRA-X UPGRADE FOR SIEMENS WHOLE BODY 7T TERRA MRI SYSTEM - OVER THE PAST THREE DECADES, MRI HAS BECOME INDISPENSABLE IN BIOMEDICAL RESEARCH FOR DIAGNOSING AND MANAGING DISEASES. THE QUALITY OF MRI IMAGES PER UNIT SCAN TIME IS SIGNIFICANTLY INFLUENCED BY THE INTRINSIC SIGNAL-TO-NOISE RATIO. NUMEROUS INSTITUTIONS HAVE ACQUIRED OR ARE IN THE PROCESS OF ACQUIRING 7T SCANNERS DUE TO THEIR CAPABILITY OF PROVIDING COMPREHENSIVE INSIGHTS INTO HUMAN PHYSIOLOGY THAT ARE UNATTAINABLE AT LOWER FIELD STRENGTHS. DESPITE THESE ADVANTAGES, HIGH- FIELD MRI ENCOUNTERS CHALLENGES SUCH AS INHOMOGENEOUS RF FIELDS, WHICH CAN AFFECT TISSUE CONTRAST AND OBSCURE SUBTLE PATHOLOGICAL CHANGES. PARALLEL TRANSMIT ARRAYS (PTX) CAN HELP ADDRESS THESE ISSUES. OUR 7T MRI SCANNER AT THE UNIVERSITY OF PENNSYLVANIA POSSESSES PTX CAPABILITY BUT REQUIRES AN UPGRADE TO ENHANCE WORKFLOW EFFICIENCY AND IMAGING QUALITY. MOREOVER, AS T2 RELAXATION TIMES OF TISSUES DECREASE AT HIGHER FIELDS, DIFFUSION MRI STUDIES WITH SHORTER ECHO TIMES NECESSITATE IMPROVED GRADIENT STRENGTH. WE ARE REQUESTING FUNDING TO UPGRADE OUR SCANNER TO THE TERRA.X PLATFORM, WHICH INCLUDES ADVANCED HARDWARE AND SOFTWARE, AI-POWERED DEEP RESOLVE, IQ TECHNOLOGY, ONLINE MOTION CORRECTION, DYNAMIC PTX, AND ENHANCED GRADIENT STRENGTH. THIS SYSTEM WILL SUPPORT ONGOING RESEARCH ACROSS MULTIPLE GRANTS AT OUR INSTITUTION, ENCOMPASSING BRAIN IMAGING, NEURODEGENERATIVE AND METABOLIC DISORDERS, MITOCHONDRIAL METABOLISM, CANCER DETECTION, AND CARDIOVASCULAR DISEASES. THE 7T SYSTEM IS PART OF THE CENTER FOR ADVANCED MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY (CAMRIS) OF THE UNIVERSITY OF PENNSYLVANIA AND WILL BE OVERSEEN BY CAMRIS’S EXECUTIVE COMMITTEE. | $1,264,944 |